Seattle biotech company Etubics Corp. has received $4.4 million to support its efforts to develop a universal influenza vaccine with a long-lasting immune response.
The National Institute of Allergy and Infectious Diseases awarded the money so Etubics to work with the University of Texas Medical Branch to take the research to the next level.
The Seattle company will use its proprietary system for developing vaccines with long-lasting immune responses as it attempts to create a vaccine that will…
Seattle biotech company Etubics Corp. has received $4.4 million to support its efforts to develop a universal influenza vaccine with a long-lasting immune response.
The National Institute of Allergy and Infectious Diseases awarded the money so Etubics to work with the University of Texas Medical Branch to take the research to the next level.
The Seattle company will use its proprietary system for developing vaccines with long-lasting immune responses as it attempts to create a vaccine that will…